A detailed history of Wells Fargo & Company transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 4,987 shares of IGMS stock, worth $32,465. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,987
Previous 5,133 2.84%
Holding current value
$32,465
Previous $35,000 134.29%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$6.28 - $17.68 $916 - $2,581
-146 Reduced 2.84%
4,987 $82,000
Q2 2024

Aug 13, 2024

BUY
$6.51 - $11.47 $1,913 - $3,372
294 Added 6.08%
5,133 $35,000
Q1 2024

May 10, 2024

BUY
$8.68 - $17.36 $5,242 - $10,485
604 Added 14.26%
4,839 $46,000
Q4 2023

Feb 09, 2024

BUY
$3.94 - $8.79 $4,467 - $9,967
1,134 Added 36.57%
4,235 $35,000
Q3 2023

Nov 13, 2023

SELL
$6.66 - $10.64 $10,303 - $16,460
-1,547 Reduced 33.28%
3,101 $25,000
Q2 2023

Aug 15, 2023

BUY
$8.86 - $14.0 $22,406 - $35,406
2,529 Added 119.35%
4,648 $42,000
Q1 2023

May 12, 2023

BUY
$13.74 - $25.76 $27,397 - $51,365
1,994 Added 1595.2%
2,119 $29,000
Q4 2022

Feb 13, 2023

SELL
$15.45 - $26.02 $4,387 - $7,389
-284 Reduced 69.44%
125 $2,000
Q3 2022

Nov 14, 2022

SELL
$15.42 - $27.01 $185 - $324
-12 Reduced 2.85%
409 $9,000
Q2 2022

Aug 12, 2022

BUY
$13.27 - $25.5 $3,927 - $7,548
296 Added 236.8%
421 $7,000
Q1 2022

May 16, 2022

SELL
$13.42 - $29.73 $50,928 - $112,825
-3,795 Reduced 96.81%
125 $3,000
Q4 2021

Feb 14, 2022

SELL
$27.59 - $66.39 $115,353 - $277,576
-4,181 Reduced 51.61%
3,920 $115,000
Q3 2021

Nov 15, 2021

SELL
$65.76 - $90.65 $804,573 - $1.11 Million
-12,235 Reduced 60.16%
8,101 $533,000
Q2 2021

Aug 16, 2021

BUY
$57.98 - $96.6 $412,817 - $687,792
7,120 Added 53.87%
20,336 $1.69 Million
Q1 2021

May 13, 2021

SELL
$71.56 - $121.23 $599,672 - $1.02 Million
-8,380 Reduced 38.8%
13,216 $1.01 Million
Q4 2020

Feb 09, 2021

BUY
$47.41 - $115.03 $663,265 - $1.61 Million
13,990 Added 183.93%
21,596 $1.91 Million
Q3 2020

Nov 05, 2020

SELL
$43.0 - $84.01 $130,462 - $254,886
-3,034 Reduced 28.52%
7,606 $561,000
Q2 2020

Aug 13, 2020

SELL
$51.3 - $75.21 $282,303 - $413,880
-5,503 Reduced 34.09%
10,640 $776,000
Q1 2020

May 14, 2020

BUY
$31.51 - $73.75 $508,665 - $1.19 Million
16,143 New
16,143 $906,000

Others Institutions Holding IGMS

About IGM Biosciences, Inc.


  • Ticker IGMS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,969,000
  • Market Cap $189M
  • Description
  • IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...
More about IGMS
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.